Home / 2021 / February

Monthly Archives: February 2021

Spacewalking Astronauts Prep Station for New Solar Wings

CAPE CANAVERAL, FLA. – Spacewalking astronauts ventured out Sunday to install support frames for new, high-efficiency solar panels arriving at the International Space Station later this year.

NASA’s Kate Rubins and Victor Glover put the first set of mounting brackets and struts together, then bolted them into place next to the station’s oldest and most degraded solar wings. But the work took longer than expected, and they barely got started on the second set before calling it quits.

Rubins will finish the job during a second spacewalk later this week.

The spacewalkers had to lug out hundreds of pounds of mounting brackets and struts in 2.5-meter (8-foot) duffel-style bags. The equipment was so big and awkward that it had to be taken apart like furniture, just to get through the hatch.

Some of the attachment locations required extra turns of the power drill and still weren’t snug enough, as indicated by black lines. The astronauts had to use a ratchet wrench to deal with the more stubborn bolts, which slowed them down. At one point, they were two hours behind.

“Whoever painted this black line painted outside the lines a little bit,” Glover said at one particularly troublesome spot.

“We’ll work on our kindergarten skills over here,” Mission Control replied, urging him to move on.

With more people and experiments flying on the space station, more power will be needed to keep everything running, according to NASA. The six new solar panels — to be delivered in pairs by SpaceX over the coming year or so — should boost the station’s electrical capability by as much as 30%.

Rubins and Glover tackled the struts for the first two solar panels, set to launch in June. Their spacewalk ended up lasting seven hours, a bit longer than planned.

“Really appreciate your hard work. I know there were a lot of challenges,” Mission Control radioed.

The eight solar panels up there now are 12 to 20 years old — most of them past their design lifetime and deteriorating. Each panel is 34 meters (112 feet) long by 12 meters (39 feet) wide. Tip to tip counting the center framework, each pair stretches 73 meters (240 feet) longer than a Boeing 777’s wingspan.

Boeing is supplying the new roll-up panels, about half the size of the old ones but just as powerful thanks to the latest solar cell technology. They’ll be placed at an angle above the old ones, which will continue to operate.

A prototype was tested at the space station in 2017.

Rubins’ helmet featured a new high-definition camera that provided stunning views, particularly those showing the vivid blue Earth 435 kilometers (270 miles) below.

“Pretty fantastic,” observed Mission Control.

Sunday’s spacewalk was the third for infectious disease specialist Rubins and Navy pilot Glover — both of whom could end up flying to the moon.

They’re among 18 astronauts newly assigned to NASA’s Artemis moon-landing program. The next moonwalkers will come from this group.

Last week, Vice President Kamala Harris put in a congratulatory call to Glover, the first African American astronaut to live full time at the space station. NASA released the video exchange Saturday.

“The history making that you are doing, we are so proud of you,” Harris said. Like other firsts, Glover replied, it won’t be the last. “We want to make sure that we can continue to do new things,” he said.

Rubins will float back out Friday with Japanese astronaut Soichi Noguchi to wrap up the solar panel prep work and to vent and relocate ammonia coolant hoses.

Glover and Noguchi were among four astronauts arriving via SpaceX in November. Rubins launched from Kazakhstan in October alongside two Russians. They’re all scheduled to return to Earth this spring.

Source: Voice of America

CDC Latest to Endorse Johnson & Johnson Vaccine for Use in US

A U.S. Centers for Disease Control and Prevention advisory panel Sunday endorsed the Johnson & Johnson vaccine, voting overwhelmingly to recommend the shot for adults older than 18.

CDC recommendations are not binding but are widely respected by medical institutions and professionals. CDC Director Rochelle Walensky later approved the panel’s recommendations.

Sunday’s CDC endorsement came one day after the U.S. Food and Drug Administration formally authorized the use of the one-dose vaccine.

Nearly 4 million doses of the Johnson & Johnson vaccine will be distributed and available as early as Tuesday morning, according to a senior administration official. This vaccine, the third to be approved for use in the United States, will be distributed to states, tribes and territories proportional to their populations – the same way the Pfizer-BioNTech and Moderna vaccines have been distributed.

Health officials in the U.S. welcomed the third vaccine, which has been eagerly awaited largely because it requires only one shot, but officials urged Americans to receive whichever vaccine is first available to them, reiterating that all three have proved to be safe and effective.

The Johnson & Johnson vaccine is 85% effective against serious illness, hospitalization and death from COVID-19, the disease caused by the coronavirus, according to data from a study that spanned three continents. The shot kept its protection even in the countries where the South African variant is spreading.

As of Sunday evening, about 28.6 million Americans have had COVID-19 and more than 513,000 have died from the disease, according to the Johns Hopkins Coronavirus Research Center.

President Joe Biden praised the “exciting news for all Americans,” in a statement Saturday evening, also urging Americans not to let their “guard down now.”

“But I want to be clear: this fight is far from over,” he added. “I urge all Americans — keep washing your hands, stay socially distanced, and keep wearing masks. As I have said many times, things are still likely to get worse again as new variants spread, and the current improvement could reverse.”

An FDA advisory panel unanimously endorsed the vaccine Friday, paving the way for the agency’s authorization.

By the end of March, Johnson & Johnson has said, it expects to deliver 20 million doses to the U.S., and 100 million by summer, the Associated Press reported. Johnson & Johnson is also seeking authorization for emergency use of its vaccine in Europe and from the World Health Organization.

In New Zealand, residents of Auckland, a city of nearly 2 million people, began a seven-day lockdown Sunday, the second in the month since the more contagious British variant of the coronavirus emerged there.

Prime Minister Jacinda Ardern announced the lockdown Saturday because of a person who was infectious for a week but had not isolated.

“It is more than likely there will be additional cases in the community,” Ardern told a press conference Sunday, although no new cases had been recorded.

New Zealand, a nation of 5 million people, identified its first COVID-19 case on February 29, 2020, and since then has seen almost 2,400 cases of COVID-19 and 26 deaths, according to the Johns Hopkins data.

Japan reported 329 new coronavirus cases on Sunday, slightly down from 337 a day earlier, according to national broadcaster NHK.

While a state of emergency stays in effect in Tokyo and three other prefectures until after the first week of March, it was lifted in eight others a week earlier than scheduled.

In Russia, the coronavirus crisis center confirmed 11,359 new coronavirus cases on Sunday and 379 deaths in the past 24 hours. The total number of infections in the country stands at 4,246,079 to date and the death toll at 86,122.

Elsewhere, the Vatican’s ambassador to Iraq, Archbishop Mitja Leskovar, has tested positive for COVID-19. The announcement comes a week before Pope Francis’ March 5-9 trip to the country.

Leskovar, whose title is apostolic nuncio, said in a statement that he was experiencing only light symptoms so far.

“This is not going to influence the pope’s program, which is going on as planned,” he said.

France will impose weekend lockdowns in Paris and 19 other regions in early March if coronavirus infections continue to accelerate.

The Czech government announced tighter restrictions beginning March 1.

In Latin America, new containment measures were imposed in several Brazilian cities and states.

The U.S. continues to lead the world in the number of coronavirus infections, followed by India with more than 11 million infections and Brazil with more than 10.5 million.

Source: Voice of America

CNH Industrial N.V. announces the extension by one additional year to March 2026 of its syndicated credit facility

London, February 26, 2021

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) announces that it has exercised the second one-year extension option (i.e. to March 2026) of its syndicated committed revolving credit facility for € 3.9505 billion. The remaining € 49.5 million will mature in March 2025.

CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions. More information can be found on the corporate website: www.cnhindustrial.com

Contacts:

Corporate Communications

Email: mediarelations@cnhind.com

Investor Relations

Email: investor.relations@cnhind.com

Attachment

Botswana Eases COVID Restrictions Despite Rising Death Toll

GABORONE, BOTSWANA – Botswana, which saw COVID-19 deaths surpass 300 this week, has lifted a ban on alcohol sales and eased curfew restrictions. But President Mokgweetsi Masisi extended an existing curfew.

In a televised address, Masisi said rising COVID-19 cases mean the curfew will continue until the end of March. Botswana introduced a nine-hour curfew in December, but Masisi announced Friday the hours have been reduced to six.

“The curfew period restricting the movement of people will be extended from the 1st to the 31st of March 2021 and will begin at 10 p.m. to 4 a.m. daily. The government has decided to lift the suspension of the sale of alcohol with effect from 1st March, 2021. Alcohol will be sold to consumers on weekdays only,” he said.

Masisi said in lifting the alcohol ban, the government took into consideration the impact on the economy.

“Studies both scientific and anecdotal, have shown that alcohol consumption impairs judgment making it difficult in some cases to adhere to set health protocols. Although necessary at the time, the government has nonetheless been worried by the effect of the temporary ban on the sale of alcohol on the industry, and by extension, the country’s economy,” Masisi said.

The country’s alcohol industry employs more than 50,000 people.

Botswana Alcohol Industry Association president Masegonyana Madisa welcomed the decision to lift the ban.

“As the alcohol industry, we have always maintained a certain position, that is government should find a more sustainable approach to this problem that we have, which involves curbing the spread of the virus, which we have in Botswana, and at the same time balancing it with protecting the lives and livelihoods of those in the alcohol industry, including its extensive value chain.”

Meanwhile, the country’s COVID-19 Task Force team vice chairperson, Mosepele Mosepele, expressed concern over the rising death toll.

“The unfortunate report that we would like to share is the sharp increase in the number of COVID-19 fatalities. The last time we reported we stood at 254, and unfortunately today we report cumulative 300 total number of COVID-19-associated fatalities, Mosepele said.

The southern African country has recorded 28,371 COVID-19 cases and 310 deaths.

President Masisi has urged the nation to adhere to COVID-19 protocols as the country awaits the arrival of the first batch of vaccine doses in March.

Source: Voice of America

FDA Approves Johnson & Johnson Vaccine for Use in US

The U.S. Food and Drug Administration formally authorized the use of the Johnson & Johnson’s one-dose vaccine Saturday, clearing the way for shots to go into arms as early as Monday.

The Johnson & Johnson vaccine is 85% effective against serious illness, hospitalization and death from COVID-19, the disease caused by the coronavirus, according to data from a study that spanned three continents. The shot kept its protection even in the countries where the South African variant is spreading.

The one-and-done inoculation has been eagerly awaited by health officials who want to speed vaccinations in a race against the coronavirus and its worrisome mutations. As of Saturday evening, more than 28.5 million Americans have had COVID-19 and nearly 512,000 have died from the disease, according to the Johns Hopkins Coronavirus Resource Center.

Biden: Don’t let up

President Joe Biden praised the “exciting news for all Americans” in a statement Saturday evening but urged Americans not to let their “guard down now.”

“I want to be clear: This fight is far from over,” he said. “I urge all Americans — keep washing your hands, stay socially distanced and keep wearing masks. As I have said many times, things are still likely to get worse again as new variants spread, and the current improvement could reverse.”

An FDA advisory panel unanimously endorsed the vaccine Friday, paving the way for the agency’s authorization.

The one-dose vaccine is the third coronavirus inoculation approved by the FDA, after the two-dose vaccines manufactured by Pfizer-BioNTech and Moderna.

By the end of March, Johnson & Johnson has said it expects to deliver 20 million doses to the U.S., and 100 million by summer, The Associated Press reported. Johnson & Johnson is also seeking authorization for emergency use of its vaccine in Europe and from the World Health Organization.

Auckland lockdown

In New Zealand, residents of Auckland, a city of nearly 2 million people, began a seven-day lockdown Sunday, the second in the month since the more contagious U.K. variant of the coronavirus emerged there.

Prime Minister Jacinda Ardern announced the lockdown Saturday because of a person who was infectious for a week but had not isolated.

“It is more than likely there will be additional cases in the community,” Ardern told a press conference Sunday, although no new cases had been recorded.

New Zealand, a nation of 5 million people, identified its first COVID-19 case on February 29, 2020, and since then has seen almost 2,400 cases of COVID-19 and 26 deaths, according to Johns Hopkins data.

Japan reported 329 new coronavirus cases on Sunday, slightly down from 337 a day earlier, according to national broadcaster NHK.

Meanwhile, Britain’s Trades Union Congress said in a study that the pandemic had provided a “mirror to the structural racism” in Britain, with the unemployment rate for communities of color double that of their white contemporaries during the pandemic.

In Russia, the coronavirus crisis center confirmed 11,359 new coronavirus cases on Sunday and 379 deaths in the past 24 hours. The total number of infections in the country stands at 4,246,079 to date and the death toll at 86,122.

Elsewhere, the Vatican’s ambassador to Iraq, Archbishop Mitja Leskovar, has tested positive for COVID-19. The announcement comes a week before Pope Francis’ March 5-9 trip to the country.

Leskovar, whose title is apostolic nuncio, said in a statement that he was experiencing only light symptoms so far. “This is not going to influence the pope’s program, which is going on as planned,” he said.

France will impose weekend lockdowns in Paris and 19 other regions at the beginning of March if coronavirus infections continue to accelerate.

France will impose weekend lockdowns in Paris and 19 other regions at the beginning of March if coronavirus infections continue to accelerate.

The Czech government announced tighter restrictions beginning March 1.

In Latin America, new containment measures were imposed in several Brazilian cities and states.

The U.S. continues to lead the world in the number of coronavirus infections with more than 28.5 million cases, followed by India with over 11 million infections and Brazil with more than 10.5 million.

Source: Voice of America

U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy

SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. government has agreed to purchase a minimum of 100,000 doses of etesevimab (JS016 or LY-CoV016) 1400 mg and bamlanivimab (LY-CoV555) 700 mg together, according to the company’s global partner Eli Lilly and Company (NYSE: LLY). Etesevimab and bamlanivimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.

The agreement is for $210 million and doses will be delivered through March 31, 2021. The U.S. government will have the option to purchase up to an additional 1,100,000 doses through November 25, 2021, under the same terms as the base agreement and subject to agreement from Lilly, product availability and the medical need in the U.S. The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product’s administration. The federal government directs the distribution of etesevimab and bamlanivimab together.

About etesevimab(JS016)
Etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology, Chinese Academy of Science (IMCAS). Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world.

Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally.

About bamlanivimab
Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing, and results from the Phase 2 cohorts of BLAZE-1 were published in the New England Journal of Medicine and The Journal of the American Medical Association. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) by US FDA in Feb 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news. P-LLY

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Bombardier Challenger 350 Jet Most Delivered in Category for Seventh Consecutive Year, Company Also Ends 2020 With Highest Total Market Share in Fourth Quarter

MONTREAL, Feb. 26, 2021 (GLOBE NEWSWIRE) — Bombardier announced today that its best-selling Challenger 350 aircraft was the most-delivered medium category business jet in 2020, making it the category leader for a seventh consecutive year. As detailed in the General Aviation Manufacturers Association’s (GAMA) annual shipment and billings report released February 24, the company also outpaced competitors by delivering 44 aircraft in the fourth quarter of 2020. This accomplishment was driven by a record 16 Global 7500 business jet deliveries in that timeframe.

Bombardier’s comprehensive family of business jets firmly positions it to respond to the growing interest in private aviation and the enhanced safety they provide during these exceptional times.

As more people seek to avoid crowds and interest in fractional and air charter increases, the best-selling Challenger 350 aircraft is there to take passengers where they need to be, and it continues to surpass expectations while doing so.

In 2020, Bombardier announced a firm order for 10 Challenger 350 aircraft in a transaction valued at $267 million U.S. and also marked the 350th delivery of the Challenger 350 business jet, a milestone reached after only seven years in service. The best-selling Challenger 350 aircraft now features an expanded selection of sophisticated and contemporary interior design schemes, high-speed Viasat Ka-band connectivity and a refreshed cabin management system, inspired by the industry’s flagship Global 7500 business jet.

In addition to the Challenger 350 aircraft, Bombardier’s Challenger 650 business jet is a masterful expression of high-end craftsmanship and functionality. With its ideal combination of range, speed and field performance capabilities, the Challenger 650 aircraft is perfectly suited for both private and specialized missions, including medevac. The Challenger 650 aircraft is in service with many governments worldwide for various special missions.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Notes to Editors
Visit the Bombardier Business Aircraft website for more information on our industry-leading products and services.

Follow @Bombardierjets on Twitter to receive the latest news and updates from Bombardier Aviation.

To receive our press releases, please visit the RSS Feed section.

Bombardier, Challenger, Challenger 350, Challenger 650 and Global 7500 are either unregistered or registered trademarks of Bombardier Inc. or its subsidiaries.

For Information
Anna Cristofaro
Bombardier
+ 1 514-855-8678
anna.cristofaro@aero.bombardier.com